Evidence map›Paper›PMID 38893510›Full record

ArticleMolecules (Basel, Switzerland)2024

In Vitro Study of Tumor-Homing Peptide-Modified Magnetic Nanoparticles for Magnetic Hyperthermia.

Shengli Zhou, Kaname Tsutsumiuchi, Ritsuko Imai, Yukiko Miki, Anna Kondo, Hiroshi Nakagawa, Kazunori Watanabe, Takashi Ohtsuki

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shengli ZhouDepartment of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama 700-8530, Japan.
Kaname TsutsumiuchiCollege of Bioscience and Biotechnology, Chubu University, Aichi 487-8501, Japan.ORCID 0000-0002-7873-1060
Ritsuko ImaiCollege of Bioscience and Biotechnology, Chubu University, Aichi 487-8501, Japan.
Yukiko MikiCollege of Bioscience and Biotechnology, Chubu University, Aichi 487-8501, Japan.
Anna KondoCollege of Bioscience and Biotechnology, Chubu University, Aichi 487-8501, Japan.
Hiroshi NakagawaCollege of Bioscience and Biotechnology, Chubu University, Aichi 487-8501, Japan.ORCID 0000-0002-9697-164X
Kazunori WatanabeDepartment of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama 700-8530, Japan.ORCID 0000-0003-3678-636X
Takashi OhtsukiDepartment of Interdisciplinary Science and Engineering in Health Systems, Okayama University, Okayama 700-8530, Japan.ORCID 0000-0002-3183-5305

Funding

JST SPRING JPMJSP2126
6 · The paper itself

Abstract

Cancer cells have higher heat sensitivity compared to normal cells; therefore, hyperthermia is a promising approach for cancer therapy because of its ability to selectively kill cancer cells by heating them. However, the specific and rapid heating of tumor tissues remains challenging. This study investigated the potential of magnetic nanoparticles (MNPs) modified with tumor-homing peptides (THPs), specifically PL1 and PL3, for tumor-specific magnetic hyperthermia therapy. The synthesis of THP-modified MNPs involved the attachment of PL1 and PL3 peptides to the surface of the MNPs, which facilitated enhanced tumor cell binding and internalization. Cell specificity studies revealed an increased uptake of PL1- and PL3-MNPs by tumor cells compared to unmodified MNPs, indicating their potential for targeted delivery. In vitro hyperthermia experiments demonstrated the efficacy of PL3-MNPs in inducing tumor cell death when exposed to an alternating magnetic field (AMF). Even without exposure to an AMF, an additional ferroptotic pathway was suggested to be mediated by the nanoparticles. Thus, this study suggests that THP-modified MNPs, particularly PL3-MNPs, hold promise as a targeted approach for tumor-specific magnetic hyperthermia therapy.

Indexed as

Hyperthermia, InducedMagnetite NanoparticlesPeptidesCell Line, TumorHumansMagnetic FieldsNeoplasmsMagnetite NanoparticlesPeptidesferroptosismagnetic hyperthermiamagnetic nanoparticlestumor-homing peptidetumor-specific delivery

Identifiers

PMID38893510
PMCPMC11174109

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.